$1.85
0.54% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
CA59935V1076
Symbol
MIST
Sector
Industry

Milestone Pharmaceuticals, Inc. Stock price

$1.85
+0.41 28.47% 1M
+0.14 8.19% 6M
+0.18 10.78% YTD
-0.96 34.16% 1Y
-4.17 69.27% 3Y
-15.97 89.62% 5Y
-13.15 87.67% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.01 0.54%
ISIN
CA59935V1076
Symbol
MIST
Sector
Industry

Key metrics

Market capitalization $98.66m
Enterprise Value $76.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.11
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-43.82m
Free Cash Flow (TTM) Free Cash Flow $-31.18m
Cash position $76.42m
EPS (TTM) EPS $-0.90
P/E forward negative
Short interest 0.86%
Show more

Is Milestone Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Milestone Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Milestone Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.61 0.61
30% 30%
-
-0.61 -0.61
115% 115%
-
- Selling and Administrative Expenses 27 27
7% 7%
-
- Research and Development Expense 16 16
56% 56%
-
-43 -43
29% 29%
-
- Depreciation and Amortization 0.61 0.61
30% 30%
-
EBIT (Operating Income) EBIT -44 -44
29% 29%
-
Net Profit -43 -43
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Milestone Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Milestone Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025
Neutral
GlobeNewsWire
3 months ago
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline results from a multi-center, randomized, double-blind, placebo-controlled...
Neutral
GlobeNewsWire
3 months ago
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024.
More Milestone Pharmaceuticals, Inc. News

Company Profile

Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.

Head office Canada
CEO Joseph Oliveto
Employees 47
Founded 2003
Website www.milestonepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today